603 Results for: created: (01/2018 to 01/2018)

People

  1. Yahalom
    Yahalom
  2. Adusumilli
    Adusumilli
  3. Zelefsky
    Zelefsky
  4. Lee
    Lee
  5. Eguchi
    Eguchi
  6. Jones
    Jones
  7. Rimner
    Rimner
  8. Travis
    Travis
  9. Yamada
    Yamada
  10. McCormick
    McCormick

Groups

  1. Department of Medicine (200)
  2. Radiation Oncology, Department of (129)
  3. Solid Tumor Oncology Division (123)
  4. Survivorship Research (122)
  5. Surgery (121)
  6. GSK Faculty (107)
  7. Sloan Kettering Institute Postdocs (99)
  8. Center for Hematologic Malignancies (74)
  9. Hematologic Malignancies, Division of (65)
  10. Epidemiology and Biostatistics (64)
Formats
  1. Journal Article (322)
  2. Meeting Abstract (139)
  3. Book Section (138)
  4. Book Whole (2)
  5. Conference Paper (1)
  6. Editorial (1)
Groups
  1. Department of Medicine (200)
  2. Radiation Oncology, Department of (129)
  3. Solid Tumor Oncology Division (123)
  4. Survivorship Research (122)
  5. Surgery (121)
  6. GSK Faculty (107)

More Groups

People
  1. Joachim Yahalom (32)
  2. Prasad Adusumilli (27)
  3. Michael Zelefsky (24)
  4. Nancy Lee (20)
  5. David Jones (19)
  6. Takashi Eguchi (19)

More People

Years
  1. 2018 (65)
  2. 2017 (371)
  3. 2016 (4)
  4. 2015 (1)
  5. 2014 (10)
  6. 2013 (4)

More Years

Publications
  1. Journal of Thoracic Oncology (53)
  2. Cancer: Principles and Practice of Oncology. 6th ed (27)
  3. Neuro-Oncology (27)
  4. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 9th ed (25)
  5. Journal of Clinical Oncology (12)
  6. Clinical Cancer Research (11)

More Publications

Publishers
  1. Elsevier Inc. (107)
  2. Lippincott Williams & Wilkins (56)
  3. Elsevier Science, Inc. (36)
  4. Oxford University Press (34)
  5. Springer (34)
  6. Wolters Kluwer Health | Lippincott Williams & Wilkins (33)

More Publishers

Results (603)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enasidenib (AG-221), a selective oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, in patients with myelodysplastic syndromes (MDS)
    Meeting Abstract

    Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Identification of aberrant splicing events in myelodysplastic syndrome patients with splicing factor gene mutations
    Meeting Abstract

    Pellagatti, A.; Steeples, V.; Sharma, E.; Repapi, E.; Yip, B. H.; Armstrong, R. N.; Dolatshad, H.; Lockstone, H.; Taylor, S.; Giagounidis, A.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Characterization of novel oral splicing modulator, H3B-8800, identifies the mechanistic basis for its preferential lethality towards spliceosome-mutant myeloid malignancy models
    Meeting Abstract

    Buonamici, S.; Yoshimi, A.; Thomas, M.; Seiler, M.; Chan, B.; Csibi, A.; Fekkes, P.; Klimek, V.; Kumar, P.; Lee, S. C. W.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Preoperative needle biopsy and tumor spread through alveolar spaces (STAS) in resected lung adenocarcinomas
    Meeting Abstract

    Kameda, K.; Eguchi, T.; Lu, S.; Solomon, S.; Bott, M.; Jones, D.; Rekhtman, N.; Travis, W.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Immunotherapy for KRAS positive lung adenocarcinoma: Mesothelin and CA125 (MUC16) are cancer-antigen targets
    Meeting Abstract

    Hristov, B.; Eguchi, T.; Chintala, N.; Lu, S.; Bott, M.; Travis, W.; Jones, D.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Minimally invasive lobectomy is associated with lower noncancer mortality in elderly: A propensity-score matched analysis
    Meeting Abstract

    Hristov, B.; Eguchi, T.; Isbell, J.; Park, B.; Tan, K. S.; Rusch, V.; Jones, D.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A stem-cell oriented phylogeny of non-small cell lung cancers
    Meeting Abstract

    Downey, R.; Riester, M.; Wu, H. J.; Moreira, A.; Michor, F.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations after failure of prior therapy
    Meeting Abstract

    Paik, P.; Stammberger, U.; Bruns, R.; Overton, L.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Clinical activity of osimertinib in EGFR mutation positive non-small cell lung cancer (NSCLC) patients (pts) previously treated with rociletinib
    Meeting Abstract

    Gadgeel, S.; Chen, W.; Piotrowska, Z.; Goldman, J. W.; Wakelee, H.; Camidge, D. R.; Varga, A.; Yu, H.; Papadimitrakopoulou, V.; Nea, J.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • The use of immunohistochemistry improves the diagnosis of SCLC. An international reproducibility study in a demanding set of cases
    Meeting Abstract

    Thunnissen, E.; Borczuk, A.; Flieder, D.; Witte, B.; Beasley, M. B.; Chung, J. H.; Dacic, S.; Lantuejoul, S.; Russell, P.; Den Bakker, M.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save